

Indian Health Service

Division of Diabetes Treatment and Prevention



IHS Diabetes Care and Outcomes Audit Audit 2025 Orientation 2/11/2025



Today's Audit Topics

- Overview
- Process and Methods
- Changes for 2025
- Data Quality Check Overview
- WebAudit
- Resources and Audit Webpages

Indian Health Service
Diabetes Care and Outcomes Audit

Audit 2025
Instructions

January 2025



Division of Diabetes Treatment and Preventior https://www.ihs.gov/diabetes/





Diabetes Audit Team

Carmen Licavoli, MSN, ANP-BC Director, DDTP

Tiffany BrianProject Manager

Lori Butcher RPMS Developer

Renee Chase, RN Federal Lead DMS RPMS

Lani Desaulniers, MD Clinical Consultant

Jermaine Gonzales WebAudit Developer

Andrew Grisnik
DMS Project Manager

Nancy Haugen, MSN ADC Representative Great Plains Area Kristy Klinger, PharmD, BC-ADM
Diabetes Audit Consultant

Larry Layne, PhD
Diabetes Audit Data Specialist

Melanie Knight SDPI Program Coordinator

Sarah Murray, MPH, PMP DDTP Project Manager

Meera Narayanan, RD, CDCES Director, Diabetes Surveillance Alaska Area

Tracy Nelson, MSN ADC Representative Portland Area

Angela Pinto-Yazzie

DMS Software Deployment/Tester

Kelly Samuelson IT Quality Analyst, Senior

Skip SquiresDMS Technical Lead

Dorinda Wiley-Bradley, RN, CDCESDiabetes Audit Consultant

Mark Williams Visual DMS Developer

Area Diabetes Consultants and Support Staff





Abbreviations

- ADC = Area Diabetes Consultant
- AI/AN = American Indian/Alaska Native
- Audit = IHS Diabetes Care and Outcomes Audit
- BP = Best Practice = SDPI Diabetes Best Practice
- DDTP = IHS Division of Diabetes Treatment and Prevention
- DMS = RPMS Diabetes Management System
- **GPRA** = Government Performance and Results Act
- EMR = Electronic Medical Record (RPMS or other)
- I/T/U = IHS, Tribal, and Urban
- **RKM** = Required Key Measure
- RPMS = IHS Resource and Patient Management System
- SDPI = Special Diabetes Program for Indians
- **SOS** = SDPI Outcomes System









IHS Diabetes Care and Outcomes Audit 2025 Cycle

Task						20	24											20	25					
	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec
Planning																								
Prepare documentation													П											
Prepare programming specs																								
DMS programming & testing								П																
DMS beta testing																								
WebAudit programming & testing																								
Non-RPMS programming & testing																								
Data submission											Г													
Data processing																								
SAS programming																								
Final report preparation																								



What is the Audit and why do it?

What: A process for assessing diabetes care and health outcomes for American Indian and Alaska Native (AI/AN) people diagnosed with diabetes.

Why:

- 1. Work towards the goal of providing <u>all</u> patients with diabetes the **highest** quality of care, as outlined in the <u>IHS Diabetes Standards of Care</u>.
- 2. Assess the diabetes care and education provided at a facility.
 - to help identify strengths and potential areas for improvement
- Meet the requirements of the Special Diabetes Program for Indians (SDPI) grant for participation in the Annual Diabetes Audit.
- 4. To contribute to Area and IHS outcome measures and reports.



IHS Diabetes Audit (main landing page)

Division of Diabetes Treatment and Prevention (DDTP)

About Us

Clinical Training

Search DDTP and SDPI

Clinical Resources

Education Materials and Resources (Online Catalog)

Fact Sheets and Publications

Special Diabetes Program for Indians (SDPI)

IHS Diabetes Audit

WebAudit Login

WebAudit Information and Account Requests

Audit 2024/2025 Resources

Conducting An Audit

Audit Training

Audit Information RPMS/DMS

Audit Information Other EMR

Audit Help and Support

Audit - FAQ

The IHS Diabetes Care and Outcomes Audit

The IHS Diabetes Care and Outcomes Audit is a process to assess care and health outcomes for American Indians and Alaska Native people with diagnosed diabetes. IHS, Tribal, and Urban Indian health care facilities nationwide participate in this process each year by auditing medical records for their patients with diabetes.

Click on the link below or left-hand menu to find information about different Audit topics. If you have questions or need further information, contact the IHS Audit team.

- WebAudit Login
- WebAudit Info and Account Requests
- Audit 2024/2025 Resources
- Conducting an Audit
- Audit Training
- Audit Help and Support
- Audit Information RPMS/DMS
- Audit Information Other EMR
- . Audit FAQ

Important Dates



- · Audit period end date: December 31, 2024
- · RPMS/DMS patch release: January 30, 2025
- · WebAudit open:

February 13, 2025 (anticipated)

· Due date:


April 25, 2025







Clinical Resources (main landing page)



Indian Health Service Division of Diabetes Treatment and Prevention





Division of Diabetes Treatment and Prevention (DDTP)

About Us

Clinical Training

Search DDTP and SDPI

Clinical Resources

Diabetes Standards of Care and Resources for Clinician and Educators

Diabetes Treatment Algorithms

Diabetes Education Lesson Plans

Diabetes Educator Tools

Kidney Health

Education Materials and Resources (Online Catalog)

Fact Sheets and Publications

Special Diabetes Program for Indians (SDPI)

IHS Diabetes Audit

Diabetes Standards of Care and Resources for Clinicians and Educators

Blood Pressure

Blood pressure (BP) control in people with diabetes is essential to reduce the risk of diabetes complications, including heart attack, stroke, heart failure, retinopathy, and kidney disease. Hypertension (HTN) or high BP is defined as a systolic BP greater than or equal to 130 mmHg or a diastolic BP greater than or equal to 80 mmHg. Hypertension in people with diabetes is common and often requires multiple medications to achieve targeted goals.

% Resource Links

Diabetes Care Topics

» View All Topics

Recommendations At-a-Glance for All Topics

- » Online version
- » Print version [PDF 269 KB]

Clinical Practice Recommendations



Clinician & Educator Resources



Patient Education Resources



CME Training



Audits – Data Periods and Due Dates

- 1. Annual Audit: (submitted once per year)
 - Data is submitted to and processed by DDTP (via WebAudit)
 - 2025 Audit Data Collection Period: January 1, 2024 December 31, 2024
 - Due date for audit data submission: April 29, 2025
 - Data will be "locked" by DDTP in mid May for all sites.
 - Programs can no longer modify data.
- 2. Interim Audits*: (submitted any time through the year via WebAudit)
 - Can be many times per year for SDPI (RKM), Area, or local use
 - Period of care: Locally or Area determined
 - Due date: Locally or Area determined
 - *Use of Audit tools for any purpose other than the "Annual" Audit.



Audit Types: Annual vs. SDPI RKM Data vs. Interim

	Annual Audit	Interim for SDPI RKM	Interim Other
Frequency	Once per year	As many as needed	As many as needed
WebAudit Type	Annual	Interim	Interim
WebAudit Versions Available	Current year only	Current + previous year	Current + previous year
Conducted When	Feb through mid-March	One or more times a year	Any time of year
Period Covered	2025: Jan 1-Dec 31, 2024	Jan 1-Dec 31	Locally determined
Due Date	2025: 4/29/2025	2024 Final: 1/31/25 2025 Baseline: 2/28/25	Determined by Area or program
Who is included	Electronic: All eligible DM patients Manual: All or sample of eligible DM patients	SDPI Target Group	Determined by Area or program
Data reviewed by DDTP	Yes	In SOS only	No
Data used for national reports	Yes	Yes (baseline & final only)	No

Audit Participation

Participants in the Annual Diabetes Audits include:

- I/T/U health care facilities associated with an SDPI grant and others.
- IHS Service Units that have historically participated in the Audit.
- Different types of facilities:
 - Clinics
 - Health Stations
 - Hospitals
- Vary in size: <25 to >5000 patients with diabetes
- Use a variety of EMR systems: RPMS and others
 - NextGen, Athena, Cerner, and more





What does the Audit measure?

IHS Diabetes Care and Outcomes Audit, 2025

NOTE: It is highly recommended that you review the Audit 2025 Instructions prior to conducting an Audit.

Audit Period Ending Date://	Examinations (during Audit period)
Facility Name:	Foot (comprehensive or "complete", including evaluation of sensation and vascular status):
Reviewer initials:	sensation and vascular status): □1 Yes
	□₂ No
State of residence:	Eye (dilated exam or retinal imaging):
Month/Year of Birth:/	□1 Yes
Birth Sex: □1 Male	□2 No
□2 Female	Dental:
□3 Unknown	□1 Yes
Date of Diabetes Diagnosis:/	□2 No
DM Type: □1 Type 1	Depression
□z Type 2	Screened for depression (during Audit period):
Tobacco/Nicotine Use (during Audit period)	□1 Yes □2 No
Tobacco	Depression an active diagnosis (during Audit period):
Screened for tobacco use:	□1 Yes
□1 Yes	□2 No
□2 No	Education (during Audit period)
Tobacco user:	Nutrition:
□1 Yes	□1 RD
□2 No	□2 Other J
→ Tobacco cessation counseling/education received:	□4 None
□1 Yes	Physical activity:
□2 No	□1 Yes
► Electronic Nicotine Delivery Systems (ENDS)*	□z No
Screened for ENDS use:	Other diabetes:
□1 Yes	□z No
□2 No	
►ENDS user:	Diabetes Therapy
□1 Yes	Select all prescribed (as of the end of the Audit period):
□2 No	☐I None of the following
*ENDS include: vapes, vaporizers, vape pens, hookah pens, electronic	□2 Insulin
cigarettes (e-cigarettes or e-cigs), and e-pipes which contain nicotine.	☐3 Metformin [Glucophage, others]
Vital Statistics	☐4 Sulfonylurea (glipizide, glyburide, glimepiride)
Height (last recorded) : ft in	□s DPP-4 inhibitor (alogiptin (Nesino), linagliptin (Tradjenta), saxagliptin (Onglyza), sitegliptin (Januwa))
Weight (last in Audit period):lbs	□6 GLP-1 receptor agonist [dulagiutide (Trulicity), exenatide [Øyø Bydureon], liragiutide (Victora, Saxendo], livisenatide (Adlyxin), semaglutide (Ozempic, Rybelsus, Wegovy)].
Hypertension (documented diagnosis ever):	□ SGLT-2 inhibitor (bexagirlious (87enzavvy), canagirliozin (invoko dapagirliozin (Farzigo), empagirliozin (Inridiance), ertugliflozin
□2 No	(Steglatro), sotaglifloziii (Inpefa)
Blood pressure (last 3 during Audit period):	☐8 Pioglitazone [Actos] or rosiglitazone [Avandia]
Systolic Diastolic	☐9 Tirzepatide [Mounjaro, Zepbaund]
1/ mmHg	□10 Acarbose [Precose] or miglitol (Glyset)
2/ mmHg	□11 Repaglinide [Frandin] or nateglinide (Starlix)
3/ mmHg	□12 Pramlintide (Symlin)
	□13 Bromocriptine (cycloset)
	14 Colesevelam [Welchol]
	CONTINUED ON PAGE 2. Be sure to complete both pages for

Audit Form (Page 1)

- Type of Diabetes and Date of Diagnosis
- Tobacco/Nicotine Use
- Height and weight
- Blood pressure
- Exams foot, eye, dental
- Depression
- Education
- Diabetes Therapy
- More

Page 1 of 2



Service Division of Diabetes Treatment and Prevention

What does the Audit measure?

PAGE 2	1
ACE Inhibitor or ARB	Hepatitis C (HCV)
Prescribed (as of the end of the Audit period):	HCV diagnosed (ever):
□1 Yes	□1 Yes □ 2 No
□₂ No	
Commonly prescribed medications include: ACE Inhibitors: benazepril, captopril, enalapril, losinopril, lisinopril, ramipril	☐ 1 Yes☐ 2 No
ARBs: candesartan, irbesartan, losartan, olmesartan, telmisartan, valsartan	
Aspirin or Other Antiplatelet/Anticoagulant Therapy	Retinopathy
Prescribed (as of the end of the Audit period):	Diagnosed (ever):
□1 Yes	□1 Yes
□2 No	□2 No
Commonly prescribed medications include: <u>Anticogudants</u> ; apixaban (Eliquis), dabigatran (Prodoxo), edoxaban (Soveyso), enoxaparin (Lovenox), trisaroxaban (Soretto), warfarin (Comnodin) <u>Antiplatelets</u> ; aspirin, aspirin/dipyridamole (Aggrenox), cilostazol (Pletaf), ciopidogre (Prievix), prassigne (Effent), ticagerelor (Effiliat)	Amputation Lower extremity (ever), any type (e.g., toe, gor below knee):
	□₂ No
Statin Therapy	Immunizations
Prescribed (as of the end of the Audit period): □ 1 Yes □ 2 No □ 3 Allergy/intolerance/contraindication Commonly prescribed medications include: atorvastatin, fluvastatin, lovastatin,	Influenza vaccine (during Audit period): ☐1 Yes ☐2 No Pneumococcal [PCV15, PCV20, PCV21, or PP ☐1 Yes
pitavastatin, pravastatin, rosuvastatin, simvastatin	□2 No
Cardiovascular Disease (CVD)	Td, Tdap, DTaP, or DT (in past 10 years):
Diagnosed (ever):	□1 Yes
□1 Yes	□z No
□z No	Tdap (ever): □1 Yes
Tuberculosis (TB)	□≥ No
TB diagnosis (latent or active) documented (ever): □ 1 Yes □ 2 No TB test done (most recent): □ 1 Skin test (PPD) □ 2 Blood test (QFT-GIT, T-SPOT)	Hepatitis B complete series (ever): 1 Yes 2 No 3 Immune Shingrix/recombinant zoster vaccine (RZV) c (ever):
☐3 No test documented	□1 Yes □2 No
→ TB test result: □ 1 Positive	Laboratory Data (most recent result during
— □2 Negative	A1C:%
☐3 No result documented	A1C Date obtained://
If TB diagnosed and/or test result positive, treatment initiated	Total Cholesterol: mg/dL
(e.g., isoniazid, rifampin, rifapentine, others):	
□1 Yes	HDL Cholesterol:mg/dL
□₂ No	LDL Cholesterol:mg/dL
□3 Unknown	Triglycerides: mg/dL
If TB result negative, test date:	Serum Creatinine: mg/dL
	eGFR:mL/min/1.73 n
Date:/	Quant UACR':mg/g ('Quantitative urine albumin-to-creatinine ratio)

Audit Form (Page 2)

- Other medications
- Hepatitis C
- Immunizations
- Laboratory test results: A1C, lipids, kidney function
- Comorbidities: CVD, TB, retinopathy, amputation

There are changes (almost) every year!



th Service Division of Diabetes Treatment and Prevention





Data measures collected in the 12-month (Audit) period:

- Tobacco screening and use
- Weight
- Blood pressure
- Education
- Exams
- Labs



Exceptions:


- Height (last ever)
- TB test/results/treatment (ever)
- Immunizations (except flu)
- Health conditions (e.g., HTN, CVD)
- Medications (as of Audit period end)

Look for key words, such as: "Audit period", "ever"



Data Collection: Measures

•For most measures <u>one</u> response is selected or provided for each patient.




Data Collection: Special Cases

Special Cases:

- Skip patterns: Some items will be skipped, based on response to previous item.
 - a. Tobacco/ENDS use
 - b. Tobacco cessation
 - c. TB items
 - d. HCV screening (example)
- Diabetes therapy: Select all that apply.

Note: if 1 is checked = patient is not on any diabetes medications.




Diabetes Therapy
Select all prescribed (as of the end of the Audit period):
□1 None of the following
□2 Insulin
₹3 Metformin [Glucophage, others]
☐4 Sulfonylurea [glipizide, glyburide, glimepiride]
☐5 DPP-4 inhibitor [alogliptin (Nesina), linagliptin (Tradjenta), saxagliptin (Onglyza), sitagliptin (Januvia)]
Me GLP-1 receptor agonist [dulaglutide (Trulicity), exenatide (Byetta, Bydureon), liraglutide (Victoza, Saxenda), lixisenatide (Adlyxin), semaglutide (Ozempic, Rybelsus, Wegovy)]
□7 SGLT-2 inhibitor [bexagliflozin (Brenzavvy), canagliflozin (Invokana), dapagliflozin (Farxiga), empagliflozin (Jardiance), ertugliflozin (Steglatro), sotagliflozin (Inpefa)]
☐8 Pioglitazone [Actos] or rosiglitazone [Avandia]
☐9 Tirzepatide [Mounjaro, Zepbound]
□10 Acarbose [Precose] or miglitol [Glyset]
□11 Repaglinide [Prandin] or nateglinide [Starlix]
□12 Pramlintide [Symlin]
□13 Bromocriptine [Cycloset]
□14 Colesevelam [Welchol]



Data Collection: Special Cases

Special Cases:

- Skip patterns: Some items will be skipped, based on response to previous item.
 - a. Tobacco/ENDS use
 - b. Tobacco cessation






Results processed through the WebAudit

Input=data file or paper forms

Output=reports and graphs



Sample page from WebAudit

There are changes every year!

Audit Report (Output)

IHS Diabetes Care and Outcomes Audit - WebAudit Audit Report for 2025 (Audit Period 01/01/2024 - 12/31/2024) Facility: Test21 LB

Annual Audit

959 charts were audited from 959 patients determined to be eligible by Test21 LB. Unless otherwise specified, time period for each item is the 12-month Audit Period.

	# of Patients (Numerator)	# Considered (Denominator)	Percent	Area Percent	IHS Percent
Birth Sex					
Male	389	959	41%		
Female	570	959	59%		
Unknown	0	959	0%		
Age					
< 20 years	36	959	4%		
20-44 years	144	959	15%		
45-64 years	402	959	42%		
≥ 65 years	377	959	39%		
Diabetes Type					
Type 1	34	959	4%		
Type 2	925	959	96%		
Duration of Diabetes					
< 1 year	5	959	1%		
< 10 years	79	959	8%		
≥ 10 years	506	959	53%		
Diagnosis date not recorded	374	959	39%		

Audit Processes and Methods

From Patient Encounters to Audit Data

Throughout the year patient encounters take place: (visits)

- in-person or telehealth visits with providers
- medication refills (pharmacy)
- lab tests (laboratory)
- immunizations (nurse visit, immunization clinics, pharmacy)
- education (DSMES, MNT, other)
- other (optometry, dental)
- Visit information is documented in the EMR (or paper chart).
 - Check with Health Information Management (HIM)
- Look for other (historical) information that might be documented.
 - TB diagnosed >10 years ago





- Notify your Area Diabetes Consultant that you are planning to start Audit activities.
 - Especially if new to submitting audit data.
 - Transitioned from RPMS to other EMR during the Audit Period.
- Gather and review resources and materials.
 - From DDTP: <u>Audit resources webpage</u>
 - Local: Previous year's reports, site specific documentation, others





- Review audit process for method(s) of submission
 - Use available Audit Resources
- Update Registers or List
 - Determine who should be audited Audit Group.
- Additional preparations
 - RPMS/DMS users:
 - Review taxonomies and then update taxonomies, as needed.
 - BDM (DMS) v2. Patch 18 is installed
 - Non-RPMS:
 - Review updated Data File Specifications and Code List for audit measures for data capture and reporting.



Review the Audit Process (cont.)

- Create an Audit Data file (for the 12-month audit period).
 - Create according to data file specifications. (non-RPMS)
 - Upload data file into the WebAudit program (RPMS/Non-RPMS)
- Review Audit Reports for all means of submission.
 - Manual, DMS, other EMR
- Clean up audit data using:
 - Data Quality Check Reports (WebAudit and DMS)
 - Trends Graph (WebAudit)
 - Annual Data Reports (WebAudit)
- Correct or verify data in the Data Quality Check Report.
 - Note in the Comments section and change in the Record, if needed.





Division of Diabetes Treatment and Prevention (DDTP)

About Us

Clinical Training

Search DDTP and SDPI

Clinical Resources

Education Materials and Resources (Online

Fact Sheets and Publications

Special Diabetes Program for Indians (SDPI)

IHS Diabetes Audit

WebAudit Login

WebAudit Information and Account Requests

Audit 2024/2025 Resources

Conducting An Audit

Audit Training

Audit Information RPMS/DMS

Audit Information Other EMR

Audit Help and Support

Audit - FAQ

Nutrition

Contact Us

Audit/SOS Login

Audit 2024/2025 Resources

Audit 2025 Resources

Instructions and Forms

Carefully read the Audit Instructions document and review the Audit Form before beginning your Audit, even if you have conducted an Audit before.

- Audit 2025 Instructions [PDF 862 KB]
- Audit 2025 Form [PDF 188 KB]

Checklists

To facilitate completion of all steps in the annual Audit process, refer to the appropriate checklist.

Electronic Audit Checklist 2025 for Other Electronic Medical Record Systems [Word – 49]

Resource and Patient Management System (RPMS) Diabetes Management System (DMS) Materials

. Audit 2025 Code List [Excel - 438 KB]

Audit 2024 Resources

Checklists

To facilitate completion of all steps in the annual Audit process, refer to the appropriate

- . Manual Audit Checklist 2024 [Word 55 KB]
- . Electronic Audit Checklist 2024 for RPMS [Word 46 KB]

Resource and Patient Management System (RPMS) Diabetes Management System (DMS) Materials

January 2024 DMS Manual (PDF – 6.2 MB)

Additional Resources

. Diabetes Standards of Care and Resources for Clinicians and Educators

Important Dates



Annual Audit 2025

- · Audit period end date: December 31, 2024
- · RPMS/DMS patch release: January 24, 2025
- · WebAudit open:

February 1, 2025 (anticipated)

· Due date: March 15, 2025





Identifying Patients to Audit: Inclusions and Exclusions



Identifying the correct group of people to audit is key!



Inclusion Criteria for 2025 DM Audit

Section 2. Identifying Patients to Audit: Inclusions and Exclusions

A critical task in performing the Audit is determining which diabetes patients to include. General guidance for identifying these patients is provided below.

First, identify patients who meet all of the following criteria:

- 1. Have a diagnosis of diabetes mellitus.
- 2. Are American Indian or Alaska Native.
- 3. Have **at least one visit** (in person or telehealth) with a diagnosis of diabetes as a purpose of visit to any of the following clinics during the one-year Audit period (numbers in parentheses are IHS specific clinic codes):
 - a. General (01)
 - b. Diabetic (06)
 - c. Internal Medicine (13)
 - d. Pediatric (20)
 - e. Well Child (24)
 - f. Family Practice (28)
 - g. Chronic Disease (50)
 - h. Endocrinology (69)
 - i. Pharmacy Primary Care Clinic (D5)

New







Active patients with diagnosis of diabetes, seen in a primary care clinic during audit period in a Register or List.

Entire DM Register or List.

All have a diagnosis of diabetes.

Lost to Follow up patients in your Register or List

Inactive patients in the Register or List





Exclusion Criteria for 2025 DM Audit

Then, exclude patients who:

- 1. Received most of their primary care during the Audit period outside of your facility.
- 2. Are currently on dialysis AND received most of their primary care during the Audit period at the dialysis unit.
- Died before the end of the Audit period.
- Were pregnant during any part of the Audit period.
- 5. Have prediabetes (as determined by documented diagnosis of prediabetes, impaired fasting glucose [IFG], impaired glucose tolerance [IGT], or elevated A1C level).
- 6. Moved permanently or temporarily before the end of the Audit period.



Audit Group vs SDPI Target Group



DM Audit Group vs SDPI Target Group: examples




1. No overlap: diabetes prevention only Target Group Guidance:

Select your Target Group from adults and/or youth who are at risk for developing diabetes.



3. SOS subset of Audit (SDPI includes only some diabetes patients)



2. Some overlap: education or tobacco use screening. Target Group Guidance:

Select from adults and/or youth with diabetes or at risk for developing diabetes



4. Audit subset of SOS(SDPI includes all community members)

DM Audit Group vs SDPI Target Group: examples

5. Total overlap not likely.

a. Generally, SDPI Target Group number is fixed for the year.



b. People with diabetes are added or removed from the Diabetes Register/List during the year.


Manual Audit Data Submission

















IHS Diabetes Care and Outcomes Audit, 2025 ended that you review the <u>Audit 2025 instructions</u> prior to conducting a

Audit Period Ending Date://	Examinations (during Audit period)
Facility Name:	Foot (comprehensive or "complete", including evaluation of sensation and vascular status):
Reviewer initials:	Di Yes
State of residence:	D₂ No
Month/Year of Birth: /	Eye (dilated exam or retinal imaging):
Birth Sex: 🗀 Male	□: Yes
Dr. Female	D3 No
Th Uningway	Dental:
Date of Diabetes Diagnosis: / /	D: Yes
DM Type: D: Type 1 D: Type 2	Depression Screened for depression (during Audit period):
	DI Yes
Tobacco/Nicotine Use (during Audit period)	Cz No
Tobacco	Depression an active diagnosis (during Audit period):
Screened for fobacco use:	Dt Yes
□1 Yes	□2 No
□z No	Education (during Audit period)
→ Tobacco user:	Nutrition:
□ 1 Yes	□1 RD □ Both RD and Other
□2 No	□2 Other)
L. Tobacco cessation counseling/education received:	□s None
□; Yes	Physical activity:
□2 No	D: Yes
Sectronic Nicotine Delivery Systems (ENDS)*	
Screened for ENDS use:	Other diabetes:
□; Yes	Dz No
□2 No	
◆ENCS user:	Diabetes Therapy
□1 Yes-	Select all prescribed (as of the end of the Audit period):
□2 No	☐s None of the following
'ENDS include: vaper, vaporizers, vape pens, hookah pens, electronic	□ z kroulin
igarettes (e-cigarettes or e-cigs), and e-pipes which contain nicotine.	🖂 Metformin
Wital Statistics	☐4 Sulfonylures (s)-curio, p(r)-curio, p(r)-curio)
Height (last recorded) :ftin	Ds DPP-4 inhibitor (ave. 10 or al., 1997 10 or 1
	☐s GLP-1 receptor agonist May 11 11 11 11 11 11 11
Weight (last in Audit period); lbs	Applicate impulse (years), distribut, mustake balancer.
Hypertension (documented diagnosis ever):	magicals (Commission a regard)
□: Yes	Dr SGLT-2 inhibitor i magnino i ferromo i arraphine
□: No	100/00/15 policy throat production
Blood pressure (last 3 during Audit period):	☐s Pioglitazone 1 or rosiglitazone
Systolic Diastolic	De Tirzepatide (************************************
1/	Dis Acarbose or mightol
2/ mmlig	Dss Repaglinide or nateglinide
3/ mmitg	Claz Pramiletide (1999)

CONTINUED ON PAGE 2. Be sure to complete both pages for

vice Division of Diabetes Treatment and Prevention



Manual Audit: Gather Data

- Select charts to review for eligible patients according to 2025 Audit Instructions.
 - All or a random sample.
 - Random sample generally used for Manual Audits and larger audit populations.
 - Use the Audit Sample Sizes chart to determine number of charts to audit.
 - 2025 Audit Instructions (pg. 12-14)
 - The number needed statistically valid results depends on the number of patients at your facility that meet the eligibility criteria for the Audit.
- Review medical record for each selected patient.
- Complete one Audit Form for each record.
 - Check off every box on the form.
 - Exception: Skip patterns.





Audit Sample Size – Random Sample

Tabl	e 2.	Audit	Samo	le	Sizes
Iabi	C 2.	Audit	Janip		JILCS

D	-4	9
Page	-1	. 3
9-		\sim

Population (# eligible diabetes patients)	90% Certainty Within 10% (Recommended)	90% Certainty Within 5%	95% Certainty Within 10%	95% Certainty Within 5%
<30	all	all	all	all
30	21	27	23	I 28
40	25	35	28	36
50	29	42	33	44
60	32	49	37	52
70	34	56	40	59
80	37	62	44	66
90	39	68	46	73
100	40	73	49	79
110	42	78	51	86
120	43	83	53	91
130	44	88	55	97
140	46	92	57	103
150	47	96	59	108
160	48	101	60	113
170	48	104	61	118
180	49	108	63	123
190	50	112	64	127
200	51	115	65	132
220	52	121	67	140
240	53	127	69	148





2025 Paper Audit Form

354 0 151 2 0 3 C 7 L. L. L	 Land the State of All Control
Audit Period Ending Date://	Examinations (during Audit period) Foot (comprehensive or "complete", including evaluation of
Facility Name:	sensation and vascular status):
Reviewer initials:	□i Yes
State of residence:	□2 No
Month/Year of Birth: /	Eye (dilated exam or retinal imaging):
V SCALLAN, N. CONT.	□1 Yes
Birth Sex: □1 Male □2 Female	□2 No
□3 Unknown	Dental:
	□1 Yes
Date of Diabetes Diagnosis:/	□2 No
DM Type: 🗀 Type 1	Depression
□2 Type 2	Screened for depression (during Audit period):
Tobacco/Nicotine Use (during Audit period)	□1 Yes □2 No
Tobacco	
Screened for tobacco use:	Depression an active diagnosis (during Audit period): 1 Yes
□1 Yes	□2 No
□2 No	Education (during Audit period)
Tobacco user:	Nutrition:
□1 Yes	□1 RD] □3 Both RD and Other
□2 No	2 Other
→ Tobacco cessation counseling/education received:	□4 None
□1 Yes	Physical activity:
□z No	□1 Yes
Electronic Nicotine Delivery Systems (ENDS)	□2 No
Screened for ENDS use:	Other diabetes:
□1 Yes	□2 No
□2 No	
ENDS user:	Diabetes Therapy
□1 Yes	Select all prescribed (as of the end of the Audit period):
□2 No	□1 None of the following
*ENDS include: vapes, vaporizers, vape pens, hookah pens, electronic	□z Insulin
cigarettes (e-cigarettes or e-cigs), and e-pipes which contain nicotine.	3 Metformin [Glucophage, others]
Vital Statistics	4 Sulfonylurea [glipizide, glyburide/glimepiride]
Height (last recorded) : ft in	□5 DPP-4 inhibitor (alogliptin (Nesino), linagliptin (Trantjento), savagliptin (Onglyzo), sitagliptin (Janivvo))
Weight (last in Audit period): lbs	☐6 GLP-1 receptor agonist (dulaglutide (774/licity), avenatide (8yetta)
Hypertension (documented diagnosis ever):	Bydureen), liraglutide (Victoza, Saxenda). lixaenatide (Adiyun), semagiutide (Ozempic, Rybelsus, Wegovy))
□1 Yes □2 No	☐7 SGLT-2 inhibitor (bexagliflozin (Brenzovvy), canagliflozin (Invokano), dapagliflozin (Farniga), empagliflozin (Jardiance), ertugliflozin
Blood pressure (last 3 during Audit period):	(Stegiotro), sotagliflozin (Inpefa)) S Pioglitazone (Actos) or rosiglitazone (Avandia)
Systolic Diastolic	☐9 Tirzepatide [Mounjaro, Zepbounii]
1/ mmHg	☐10 Acarbose (Precose) or miglitol (Glyset)
2/ mmHg	□11 Repaglinide (Prandin) or nateglinide (Starlix)
3/mmHg	□12 Pramlintide [Symin]
- Inning	☐13 Bromocriptine [Cycloset]
	□14 Colesevelam [Welcho/]
	CONTINUED ON PAGE 2. Be sure to complete both pages for

nent and Prevention



Manual Audit: Data Entry

Data Entry into the WebAudit:

- Do not submit anything other than a blank space for missing or unknown data (e.g., not 0).
- Examples: blood pressures and some lab values

Blood Pressure (last 3 during Audit period):	Systolic 1:	Diastolic 1
	mm Hg I	mm Hg
If no Blood Pressure	Systolic 2	Diastolic 2
measurements during the Audit Period - leave blank.	mm Hg	mm Hg
	Systolic 3	Diastolic 3
	mm Hg	mm Hg
Blood Pressure (last 3 during Audit period):	Systolic 1:	Diastolic 1
	OX	×
Do not out a NOU if the we	Systolic 2	Diastolic 2
Do not enter "0" if there are no values to enter.	%	×
	Systolic 3	Diastolic 3
	×	×





Manual Audit Check List

IHS Division of Diabetes Treatment and Prevention Annual Diabetes Care and Outcomes Audit 2025

Manual Audit Checklist January 2025

Step	1.0 Preparation	Completed?
1.1	Let your <u>Area Diabetes Consultants</u> ¹ know that you are planning to start conducting your Audit.	
1.2	Review the detailed <u>Audit 2025 Instructions</u> ² with particular attention to the section on conducting a manual Audit.	
1.3	Review the Diabetes Registry or list of diabetes patients for your facility and update, as needed.	

Step	2.0 Complete Audit Forms	Completed?
2.1	From a list of eligible diabetes patients, randomly select the appropriate number of charts to review <u>Audit 2025 Instructions</u> ² , pp. 12-14.	
2.2	Download the <u>Audit 2025 Form</u> ³ and make as many copies of the form as you have charts to review.	
2.3	Perform the chart audits and complete a paper Audit form for each chart reviewed. Be sure to complete all relevant items.	

Step	3.0 Enter and Review Data via the WebAudit	Completed?
3.1	Request a WebAudit account if you do not already have one. For more information, visit the IHS Division of Diabetes <u>Audit website</u> ⁴ .	
3.2	Login to the WebAudit: Go to the Audit website and click on the "Log in" button.	
3.3	Go to Facility Administration tab or icon to enter number of diabetes patients. Note: Enter the number of patients that meet the Audit inclusion and exclusion criteria (i.e., eligible patients).	
3.4	 Go to Data Processing tab or icon to enter data for each completed Audit form. Click on Date Entry and under Audit Type: select Annual Audit Follow prompts to enter data. Use tab key to move to the next prompt. Save data entered. Go to the next record and repeat steps for each record to be entered. 	



Electronic Audit Data Submission







Other EMR Programming

Electronic Data Submission

21 57% 21 5%

21 24% 21 76%


21 29%


21 0%












A1C > 9.0





Electronic Audits: RPMS vs. other EMRs

- Below are selected items. There are many other differences!
- Resources for both are available on the Audit website.

Activity	RPMS	Other EMR
Software programming: done by	IHS	Software company or vendor
Identify eligible patients	Registry or QMAN search	System dependent
Preparation	-Install DMS patch 18 -Update site-populated taxonomies -Review & update registry OR create list of diabetes patients	System dependent
Education documentation	RPMS-specific coding	System dependent



Tools for Other EMRs: Code List and Data File Specifications

- The Code List and Data File Specifications documents are useful for data capture and the creation of the Audit Data File.
- Code List: DM EDUCATION tab:

-38	А	В	С	D
1	CODE	* Description	Code type	Provider Type
2	95249	Personal CGM - statup/training	CPT	MA, RN, LPN or CDCES directed by a physician or other qualified HCP
3	95250	Professional CGM -startup/training	CPT	MA, RN, LPN or CDCES directed by a physician or other qualified HCP
4	95251	CGM analysis, interpretation and report	CPT	MA, RN, LPN or CDCES directed by a physician or other qualified HCP
5	98960	Education and training using a standardized curriculum, face-to-face; individual	CPT	Qualified nonphysician HCP
6	98961	Eudcation and training using a standardized curriculum, face-to-face; group 2-4 patients	CPT	Qualified nonphysician HCP
7	98962	Eudcation and training using a standardized curriculum, face-to-face; group 5-8 patients	CPT	Qualified nonphysician HCP
8	G0108	DM Outpatient self-management training services, individual	CPT	DSMT ADCES Accredited or ADA Recognized Only
9	G0109	DM Outpatient self-management training services, group	CPT	DSMT ADCES Accredited or ADA Recognized Only
10	99605	Medication Therapy Management services provided by a pharmacist - face-to-face; initial 15 min; new pt	CPT	Pharmacist 13
	99606	Medication Therapy Management services provided by a pharmacist - face-to-face; initial 15 min; estab pt	CPT	Pharmacist
11				
4	·	27_DENTALEXAM 28_DEPSCREEN2 29_DEPDX2 30_DIETINSTR 31_EXERCISE 32_DMEDUC 34_1	TXINSUL 35	_TXMETFORM 36_TXSUREA 37_TXDPP4 38_TXGLP1MED 39_TXSC

Data File Specifications for 2025

IHS Diabetes Care and Outcomes Audit Data File Specifications for 2025

General Information

- 1. Data File Format: Delimited text, with the following general requirements.
 - a. Delimiter must be the ^ symbol, not a tab, space, or any other character.
 - b. Line 1 contains the Audit field names in the order they appear below.
 - c. Lines 2 and beyond contain the data, with each line representing a single record/patient.
 - d. All records must contain a value or a placeholder for all fields. If there is no value for a field (because data are missing or due to skip pattern), the place holder is one blank space between the delimiters (i.e., ^ ^).
 - e. Do not submit anything other than a blank space for missing or unknown data (e.g., not 0).

2. Data Fields:

- a. A list of Audit 2025 fields and basic details/requirements for each is provided on subsequent pages of this document.
- b. Extracting accurate data for many fields requires additional information, some of which is available in the Audit documentation.
- c. Other information is specific to the health record system being used and must be determined locally, including documentation of medications and education.

Read through carefully.

9-page document



Data File Specifications for 2025

List of Audit Data Fields

Order	Field Name	Description	Timeframe	Format/Values/Units	Comments
1	AUDITDATE	Ending date of the one-year Audit period: 12/31/2024for Annual Audit 2025	N/A	mm/dd/yyyy	
2	FACILITYNA	Name or abbreviation for the facility	N/A	Character (max length=20)	For confirmation purposes only, since the WebAudit will automatically supply and display the name.
3	REVIEWER	Reviewer's initials	N/A	Character (max length=3)	
4	STATE	Postal abbreviation for last known state of residence	N/A	Character (max length=2)	Do not populate if patient's address is outside of the US (e.g., in Canada).
5	MOB	Month of birth	N/A	# with value 1-12	
6	YOB	Year of birth	N/A	уууу	
7	SEX	Birth sex	N/A	# field with: 1=Male 2=Female 3=Unknown	
8	8 DODX Date of diabetes diagnosis		N/A	mm/dd/yyyy	If only year is known, use value 07/01/yyyy. If only month and year are known, use 15 for the day. Leave blank if year or entire date is unknown.
9	DMTYPE	Diabetes type	N/A	# field with: 1=Type 1 2=Type 2 (or uncertain)	
10	TOBSCREEN	Screened for tobacco use	Audit period	# field with: 1=Yes 2=No	
11	TOBACCOUSE	Tobacco use	Audit period	# field with: 1=Yes 2=No	Populate only if TOBSCREEN value is 1=Yes.

Indian Health Service Division of Diabetes Treatment and Prevention

Audit Data File: sample



Blank space here

- Can be viewed using Notepad, Word, Excel or other software that allows viewing of text files.
- The Audit export file contains raw data; don't edit anything here.
- Only the original text file can be uploaded into the WebAudit.





Electronic Audit Checklist for RPMS

IHS Division of Diabetes Treatment and Prevention Annual Diabetes Care and Outcomes Audit 2025

Electronic Audit Checklist: IHS Resource and Patient Management System (RPMS)

January 2025

Step	1.0 Preparation	Completed?
1.1	Let your <u>Area Diabetes Consultant</u> ¹ know that you are planning to start conducting the Audit.	
1.2	Review the detailed <u>2025 Audit Instructions</u> ² with particular attention to the section on conducting an electronic Audit using RPMS.	
1.3	Install the RPMS patch for Audit 2025: Diabetes Management System (DMS) Version 2.0, Patch 18. Your facility's Clinical Application Coordinator (CAC) or local RPMS support team will need to do this.	
1.4	Review the <u>DMS User Manual (January 2025)</u> ³ . Pay particular attention to the information for Audit 2025, including the Summary of Changes on pp. 2.	
1.5	 Review and update site-populated taxonomies. a. Run and review the "List Labs/Medications Used at this Facility" report. (DMS menu options: AS -> LMR) b. Run and review the "Check Taxonomies for the 2025 DM Audit" report. (DMS menu options: AS -> TC) c. Update taxonomies, as needed. (DMS menu options: AS -> TU) Tips: See pp. 5-8 of this document for a list of site-populated taxonomies. Review Labs/Medications Used list(s) with laboratory and pharmacy staff when updating these taxonomies. Remove lab panels. Populate combination medications in all appropriate taxonomies. 	





Electronic Audit Checklist for other Electronic Medical Records Systems

IHS Division of Diabetes Treatment and Prevention Annual Diabetes Care and Outcomes Audit 2025

Audit Checklist: Electronic Medical Record (EMR) Systems Other than RPMS
October 2024

Notes:

- This checklist provides general guidance on programming for the IHS Diabetes Audit¹ (Audit). It does not
 provide detailed information for any particular EMR system.
- There is a separate checklist for conducting Audits using the IHS Resource and Patient Management System (RPMS).
- · Follow HIPAA guidelines for patient data confidentiality.
- · Contact the IHS Audit team (diabetesaudit@ihs.gov) with any questions or to request resources.

Step	1.0 Preparation	Completed?
1.1	Notify your Area Diabetes Consultant ² (ADC) that you are planning to start Audit activities.	
1.2	View recorded webinar: Audit 2025 Orientation for Non-RPMS Electronic Audits (available on the <u>Audit training page</u> ³).	
1.3	Gather and carefully review resources for current year (2025). These are available on the Audit resources page ⁴ and include:	
	 Audit Form Audit Instructions (pay particular attention to Appendix A: IHS Diabetes Care and Outcomes Audit Data File Specifications for 2025) Excel file of code lists 	
1.4	Identify technical personnel, including programmers, for your facility. These individuals may be in-house or with an external EMR vendor.	
1.5	Connect programmer(s) to key staff at your facility with knowledge relevant to the Audit process. Consider including staff from multiple departments: diabetes and/or Special Diabetes Program for Indians (SDPI) program; information technology (IT), medical, nursing, pharmacy, lab, optometry, dental, health information management (HIM), billing and coding, quality improvement, and administration.	
1.6	Develop a strategic plan that may include: Team member assignment Consistent and ongoing communication among team members Testing plan Timelines	





Diabetes WebAudit



The IHS Diabetes Care and Outcomes Audit is a process to assess care and health outcomes for American Indians and Alaska Natives with diagnosed diabetes. IHS, Tribal and Urban Indian health care facilities nationwide participate in this process each year by auditing medical records for their patients with diabetes.

Login





The Diabetes WebAudit System

- The WebAudit is a set of internet-based tools for Audit data entry, uploading files from electronic Audits, data processing, and reporting.
- Data submitted into the WebAudit for all data processing and report tools are the same.
- Data and reports from previous audits are retained in the system.
 - Audit Reports go back to 2008 for many sites.
- At least one person from each facility has access.
 - In general, individuals directly involved with conducting the Diabetes Audit.
- Interim Audits can be submitted at anytime.



WebAudit Access and More

WebAudit access

- New Register for an IHS Web Account (system separate from WebAudit)
- Request WebAudit access (SOS)

WebAudit – Username

If you ever had access but don't remember your login info, contact us instead
of creating a new account.

WebAudit – User tip

- Login In your browser, bookmark the <u>Audit website</u> or <u>WebAudit login page</u>.
- Data Entry Use the tab and number keys.





Division of Diabetes Treatment and Prevention (DDTP)

About Us

Search DDTP and SDPI

Clinical Training

Clinical Resources

Education Materials and Resources (Online Catalog)

Fact Sheets and Publications

IHS Diabetes Audit

WebAudit Login

WebAudit Information and Account Requests

Audit 2024 Resources

Conducting An Audit

Audit Training

Audit Information RPMS/DMS

Audit Information Other EMR

Audit Help and Support

WebAudit Information and Account Requests

The WebAudit is a set of internet-based tools for Audit data entry, uploading files from electronic Audits, data processing, and reporting. The WebAudit tools can be used to conduct the Annual Audit and Interim Audits throughout the year.

With the WebAudit's point-and-click interface, users can quickly and easily enter or upload Audit data into a secure, centralized database. They can then view and edit their data, check it for errors, or download it in Excel format for local use. Summary reports are also available for the current year and previous years. Graphs with results over time in Excel format are also available for download.



- Requirements: To use the WebAudit, you must have a computer with internet access and an internet browser, such as Microsoft Edge.
- . Documentation: Once logged into the WebAudit, users will find brief instructions on each page.
- Request Access: Each user must have their own account.
 - Register for an IHS Web Account, if you do not already have one. The Username and Password for this account are separate
 from the account you use to log in to your local network.
 - Request WebAudit access. Type in the Username and Password for your IHS Web Account and follow the instructions to request access.
 - Most requests for WebAudit accounts will be approved in 24 hours or less. You will receive an email message when your request is approved.
 - 4. Contact the IHS Audit team if you have any questions or problems.
- 5. If you already have a WebAudit account, log in and/or reset your password.

Log in

• Request Username: Contact the IHS Audit team if you have a WebAudit account but do not remember your username.




Submit and Review Data via the WebAudit

	Step	WebAudit Tool(s)
1	Enter # eligible patients (NOT number Audited)*	Enter Facility Info (Facility Information)
2	Submit data (choose one) Electronic Audit Manual Audit	Upload Data Data Entry (Data Processing)
3	Check data for potential errors → edit data as needed	Data Quality Check View/Edit Data (Audit Reports)
4	Review reports and graphs of results → edit data as needed	Audit Reports & Trends Graphs View/Edit Data (Audit Reports)
5	"Lock" data	Lock Facility Data (Facility Information)
6	Complete Audit evaluation (optional)	Link on screen and in email


^{*}Enter either the number of patients that meet the Audit inclusion and exclusion criteria (i.e., eligible patients) OR the number of people in your Target Group (if this Interim Audit is for SDPI Reporting).

Main Page (after login)





Reports Page



What's New for Audit 2025

- Documentation: User Manual updated (new release pending)
- 2. Inclusion Criteria Revision: language
- 3. Changes to Audit Form and Reports integrated throughout.
- 4. Logic changes: diabetes education, immunizations, others.
- 5. Find additional details and information:
 - 2025 DMS User Manual for Version 2.0 Patch 18
 - 2025 Audit Instructions



Logic and Reporting Changes for Audit 2025

Cardiovascular disease (CVD) Report

- Added "CVD and mean BP <140/<90" to report.
- Added "CVD and GLP-1 receptor agonist and/or SGLT-2 inhibitor currently prescribed" to report.

Dental – Added

- IHS Dental Tracking Codes: 0000 or 0190
- RPMS Dental ADA/CDT Codes: 0120, 0145, 0150, D0120, D0150, D0160, D0180, D0190, D0191
- POV ICD10 codes: Z01.20, Z01.20, Z13.84, Z29.3 [BGP DENTAL VISIT DXS]



Logic and Reporting Changes for Audit 2025

Depression Screening

Added EPDS and CPT 96127 to Depression Screening

Hepatitis B

Change logic for Complete Series Ever to include combination of 2 and 3 dose vaccines

Pneumococcal Vaccine

Added PCV21

Other Diabetes Education-Added

- CPT visit codes 98961 (Self-Management Education and Training 2-4 Pts.)
- CPT visit codes 99605 and 99606 (Medication Therapy Management)





Cardiovascular Disease: Change in report section

Cardiovascular Disease (CVD)			€
CVD diagnosed ever	16	75	21%
CVD and mean BP <130/<80 Add: CVD and mean BP <140/<90	5	16	31%
CVD and not current tobacco user* *Excludes patients not screened for tobacco use	11	15	73%
CVD and aspirin or other antiplatelet/anticoagulant therapy currently prescribed	9	16	56%
CVD and GLP-1 receptor agonist currently prescribed	4	16	25%
CVD and SGLT-2 inhibitor currently prescribed Add: CVD and GLP-1 ragonist and/or SGLT-2		16	19%
CVD and statin currently prescribed* *Excludes patients with an allergy, intolerance, or contraindication	scribed 13	16	81%





Added: Pneumococcal vaccine and Medication

Tirzepatide [Mounjaro] Add Zepbound - [Mounjaro, Zepbound] 2 75 3%

	# of Patients (Numerator)	# Considered (Denominator)	Percent	Area Percent	IHS Percent
Immunizations Add PCV21,					
Influenza vaccine during Audit period	29	75	39%		
Pneumococcal vaccine (PCV15, PCV20, or PPSV23) - ever	37	75	49%		





Other minor changes

Exams				
Foot exam - comprehensive	comprehensive or complete	25	75	33%
Eye exam - dilated exam or i	retinal imaging	30	75	40%
Dental exam		20	75	27%

Footnotes

¹For triglycerides: >150 is a marker of CVD risk, not a treatment target; >1000 is a risk marker for pancreatitis. ²Chronic Kidney Disease (CKD): eGFR<60 or UACR≥30 Quantitative UACR >=30





Change: SDPI RKM

Immunizations: Influenza			
Influenza vaccine during report period	29	75	39%
Immunizations: Pneumococcal			
Pneumococcal vaccine (PCV15, PCV20, or PPSV23) - ever	37	75	49%
Immunizations: Tetanus/Diphtheria Add PCV21,			
Td/Tdap/DTaP/DT - past 10 years	49	75	65%

Immunizations: Pneumococcal
Pneumococcal vaccine (PCV15, PCV20, 33 64 52%
PCV21 or PPSV23) - ever





2025 Audit Form Changes

2024

Vital Statistics	
Height (last ever): ft in	
Weight (last in Audit period): lbs	
Hypertension (documented diagnosis ever): □1 Yes □2 No	
Blood pressure (last 3 during Audit period):	
/ mmHg	
/mmHg	
/mmHg	•

2025

Vital Statistics	
Height (last recorded) : ft in	
Weight (last in Audit period): <u>lbs</u>	
Hypertension (documented diagnosis ever): □1 Yes □2 No	
Blood pressure (last 3 during Audit period): Systolic Diastolic	
1/ mmHg	
2/ mmHg	
3/ mmHg	

NOTE: Input remains the same – up to three values per patient. See Instructions and Data File Specifications for details.





Other minor changes

Laboratory Data (most recent result during Audit period)								
A1C:%								
A1C Date obtained://								
Total Cholesterol: mg/dL								
HDL Cholesterol: mg/dL								
LDL Cholesterol: mg/dL								
Triglycerides: mg/dL								
Serum Creatinine: mg/dL								
eGFR: mL/min/1.73 m ²								
Quant UACR*: mg/g (*Quantitative urine albumin-to-creatinine ratio)								



Data Quality Check – Brief Overview

Data Quality Check

Checks each data item and look for data that might be or are definitely incorrect.

- Two types of errors:
 - Potential: Value "might be" incorrect.
 - Example: values that are higher or lower than expected (e.g., A1c<2).
 - Definite: Value is "definitely incorrect" according to Audit logic.
 - May be found in dates and skip patterns:
 - date of diagnosis is before date of birth
 - received cessation counseling but is not a current tobacco user
- Two report sections:
 - Summary: Number of errors for each data field.
 - List: Details for each error.



Data Quality Check

Review the Summary and then the List. Look for:

- 1. Large number of errors for one or more fields. If found:
 - Stop and explore possible reasons.
 - Create and upload a new data file, if necessary.
- 2. Small number of errors for one or more fields. If found:
 - Review each one.
 - Determine if corrections are necessary.
 - a. If needed, make corrections in WebAudit and note in Comments.
 - b. If no corrections are needed, note in Comments to verify information.





Data Quality Check Summary Report - WebAudit







Data Quality Check Details List - WebAudit

There are 2 records for this facility.
5 Potential Data Errors were found.
Table sorted by Field Name ascending.





Edit	WebAudit ID	Yr/Mo of Birth	Sex	Date of Diagnosis	Field Name	Value	Error Type	Error Message	Comments
	^~	^~	0	^~	^~		^~		^~
8	1002	1960 / 7	F	06/01/1960	Date of Diabetes Diagnosis	06/01/1960	Definite	Date of Diagnosis is earlier than Date of Birth. You must check both dates and change one or both dates.	Add comment
3	1002	1960 / 7	F	06/01/1960	DM Therapy: Insulin	2	Potential	Response for this medication is inconsistent with DM type 1. Check DM type and therapy and change one or both if necessary.	Add comment
3	1001	1990 / 5	F	03/01/2022	ENDS use status	None	Potential	Missing value. Enter a value if possible.	Add comment





Electronic Audits – Common Issue

Issue: Large number of patients missing all key data fields What you'll see in the WebAudit (example):

List of Audit Potential Data Errors for 2024
Facility: Test02 Sample Data
2024 Annual Audit

Edit	WebAudit ID	Yr/Mo of Birth	Sex	Date of Diagnosis	Field Name	Value	Error Type	Error Message	Comments
3	2318	1958 / 10	M	04/02/2014	Multiple – See error message	None	Potential	Record is missing data for ALL of the key fields: weight, blood pressure, A1C, LDL value, and uACR value.	Add comment telehealth
8	2075	1948 / 9	M	04/06/2007	Multiple – See error message	None	Potential	Record is missing data for ALL of the key fields: weight, blood pressure, A1C, LDL value, and uACR value.	Add comment

Potential issue: This could result from patients not truly eligible (should be removed) OR patients only having telehealth visits during Audit period (okay).

If necessary, create and upload a new data file.



Additional Tips

- Start early!
- Maintain DM Registers or Lists.
 - Having a updated Register makes identifying those eligible for the DM Audit easier.
 - RPMS: View your Master List and share with others.
 - Update quarterly.
 - Programs transitioning to other EMRs from RPMS run a Master List and save.
- Use those Audit Check Lists.
- Data clean up an important step
 - Review the WebAudit reports especially the Data Quality Report.
 - Makes data clean up easier for ADCs and DDTP.
 - Provides a better understanding about your data.





Manual Audits: Paper forms contain patient data and should be handled according to facility policies.

Electronic Audits

- RPMS/DMS Audit data files and some reports contain patient data and should be handled according to facility policies.
- Save DMS Audit files in a secure location, as instructed by your facility.

WebAudit

- Do not give your username/password to anyone.
- Lock your workstation or log out if you need to do something else.
- Handle files and documents with patient data (from View/Download Data or Data Quality Check tool) according to facility policies.



Audit Support

1. Area Diabetes Consultants

- Area Audit Support
- Link to access ADC list: <u>Area Diabetes Consultants</u>

2. DDTP Audit team

- WebAudit & general questions
- Email: <u>diabetesaudit@ihs.gov</u> (goes to Dorinda Wiley-Bradley and Kristy Klinger)

3. RPMS (OIT Service Desk): https://www.ihs.gov/Helpdesk/

- Specific to RPMS: DMS (BDM) and Visual DMS program support
- Installation, program functionalities and service issues
- On this webpage page go to: IHS IT Self Service Portal



Audit Resources

1. IHS Diabetes Audit

- Materials: Form, Instructions, Checklists, RPMS/DMS documentation
- Training: Live, recorded, DMS
- Other information and resources
- Website: https://www.ihs.gov/Diabetes/audit/

2. Other:

- RPMS DMS recorded trainings
- Link: https://www.ihs.gov/rpms/training/recording-and-material-library/



Upcoming Audit 2025 Webinars

Trainings: (60 minutes)

Time for all trainings: 3:00 pm - 4:00 pm ET | 2pm CT | 1pm MT | 11am AKT

- RPMS Diabetes Management System (DMS) Overview: Tuesday, 2/18/2025
 - Using DMS tools focused on the DM Audit.
- Audit 2025 Reports: Tuesday, 2/25/2025
 - Review of Audit reports from the WebAudit.

All sessions will be recorded.





Questions?

